Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours

This phase I trial was designed to determine the safety and maximum tolerated dose (MTD) of tipifarnib in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Furthermore, the pharmacokinetics of each of these agents was evaluated. Patients were treated with tipifarnib...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Siegel-Lakhai, W S, Crul, M, Zhang, S, Sparidans, R W, Pluim, D, Howes, A, Solanki, B, Beijnen, J H, Schellens, J H M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2005
Aiheet:
Clinical Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361514/
https://ncbi.nlm.nih.gov/pubmed/16251868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602850
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia